Atlante Ventures, the Venture Capital Fund of the Intesa Sanpaolo Group, enters Silicon Biosystems S.p.A. with an investment of 2 million euros, in the context of a capital increase totalling 5 million euros, also underwritten by the current shareholders, in particular Innogest Capital and a group of Business Angels. The transaction was led jointly by Atlante Ventures and Innogest Capital.
Silicon Biosystems S.p.A. is a Bologna-based biomedical company that has developed a world-class innovative platform (comprising machines, chips, software and reagents) for the extraction and analysis of rare cells, based on the principle of dielectrophoresis.
“We believe that the technology developed by the Silicon Biosystems team is a point of excellence at the world level in a very promising area of oncology and prenatal diagnosis; we’ll put at the disposal of the management financial resources, ideas and networks in order to contribute to making the company successful on the international markets,” stated Davide Turco, head of Atlante Ventures.
“The strengthening of the shareholders team with the investment of the Intesa Sanpaolo Group, through the Atlante Ventures Fund, represents a recognition for the persons – in particular the researchers – who have devoted their professional life to the attainment of the current important results, and will make it possible to meet the needs of patients, thus allowing the full exploitation of the potentialities of the firm,” declared Giuseppe Giorgini, President and Managing Director of the company.